Dr. Reddy's Laboratories Limited: Business Overview, Financials & Competitive Analysis
Dr. Reddy's Laboratories Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Undervalued growth story with emerging biosimilar and GLP-1 opportunities offsetting near-term generic pricing pressures. Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. The company demonstrates strong revenue growth and strategic positioning in high-growth categories, though it faces.
What is Dr. Reddy's Laboratories Limited's industry? Dr. Reddy's Laboratories Limited (drreddys.com) operates in Pharmaceutical Manufacturing - Specialty & Generic. AskCyborg classifies Dr. Reddy's Laboratories Limited under Pharmaceutical Manufacturing - Specialty & Generic in its company registry.
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company produces over 190 medications, 60 active pharmaceut...
Cyborg Score thesis
Undervalued growth story with emerging biosimilar and GLP-1 opportunities offsetting near-term generic pricing...
Read the full analyst-debate transcript →Get the Latest Dr. Reddy's Laboratories Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeDr. Reddy's Laboratories Limited Overview
Pro stress-test →Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's operates as an integrated pharmaceutical manufacturer with a global footprint across North America, Europe, India, Russia, and emerging markets.
Strategic Profile
Pro stress-test →The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments, with the Global Generics segment manufacturing and marketing prescription and over-the-counter finished pharmaceutical products and engaging in the biologics business. Revenues grew 11% year over year to $997 million in Q1 fiscal 2026, surpassing consensus estimates, primarily driven by growth in global generics revenues.
Competitive Landscape
Pro stress-test →The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's competes with major global pharma players including Teva Pharmaceutical, Mylan/Viatris, and branded manufacturers across generics, APIs, and emerging biosimilar categories.
Industry Context
Dr. Reddy's Laboratories Limited operates in Pharmaceutical Manufacturing - Specialty & Generic.
Key facts
Founded: 1984 · Headquarters: Hyderabad, India · Revenue: $997M (Q1 FY26)